Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arecor Therapeutics PLC ( (GB:AREC) ) has provided an update.
Arecor Therapeutics plc has received positive feedback from the FDA on the design of its Phase 2 clinical study for AT278, an ultra-concentrated and ultra-rapid acting insulin, in combination with an Automated Insulin Delivery (AID) system. This feedback marks a significant milestone for Arecor, enabling faster development by using Time-in-Range (TIR) as a primary efficacy endpoint, which provides real-time insights into glycaemic variability. The study, set to commence in 2026, aims to demonstrate the economic value and patient benefits of AT278 and could potentially disrupt the insulin treatment market by addressing unmet needs in diabetes care.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics PLC’s stock is buoyed by strong technical indicators and positive corporate events, despite financial challenges typical of early-stage biotech companies. The technical analysis and corporate events significantly contribute to the overall score, highlighting market confidence and strategic growth initiatives.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a clinical stage biopharmaceutical company based in Cambridge, UK, focusing on drug development and delivery in diabetes and other cardiometabolic diseases. The company utilizes its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products and collaborates with leading pharmaceutical and biotechnology companies. Arecor’s lead product is AT278, an ultra-concentrated (500U/mL) ultra-rapid acting insulin, and it is also developing a novel oral delivery platform for peptides targeting the obesity and diabetes markets.
Average Trading Volume: 26,320
Technical Sentiment Signal: Hold
Current Market Cap: £23.98M
See more data about AREC stock on TipRanks’ Stock Analysis page.